The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary

SIMPLE SUMMARY: Few therapies are available for patients with aggressive or metastatic pituitary neuroendocrine tumours (PitNETs). Peptide receptor radionuclide therapy (PRRT), widely used to treat gastroenteropancreatic neuroendocrine tumours, has been emerging as a potential option for aggressive...

Descripción completa

Detalles Bibliográficos
Autor principal: Marques, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216433/
https://www.ncbi.nlm.nih.gov/pubmed/37345047
http://dx.doi.org/10.3390/cancers15102710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216433/
https://www.ncbi.nlm.nih.gov/pubmed/37345047
http://dx.doi.org/10.3390/cancers15102710

Ejemplares similares